KARO PHARMA AS
Score · fiscal year 2025
82of 100
How to read this: the company is ahead of 98 % of companies in the Morning class Medium in the same sector in 2025. What does this mean?
Rank in the Morning class Medium: 45 of 2,203 · What are Morning company classes?
Place in the whole sector: 888 of 38,670 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 95 and solidity 81 out of 100 among companies in the Morning class Medium in the same sector in 2025. Methodology
Against the sector
KARO PHARMA AS is 33 points above the median for companies in the Morning class Medium in the same sector in 2025.
Median score 49 among 2,198 companies.
Against companies in the Morning class Medium in the same sector in 2025: operating margin 24.6% (median 3.2%) and equity ratio 60.6% (median 32.6%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 790 MNOK | 173 MNOK |
| Operating margin | 24.6% | 3.2% |
| Profit margin | 26.0% | 3.2% |
| Return on assets | 35.7% | 11.6% |
| Equity ratio | 60.6% | 32.6% |
| Debt-to-equity | 0.65 | 2.03 |
| Current ratio | 2.39 | 1.38 |
| Revenue growth | 10.7% | 6.8% |
| Revenue per employee | 34.37 MNOK | 6.45 MNOK |
The median and “ahead of” refer to companies in the Morning class Medium in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 82, KARO PHARMA AS does better than 98% of companies in the Morning class Medium in the same sector (2,203 companies) in 2025.
Score 2023–2025
- KARO PHARMA AS
- Median: companies in the Morning class Medium in the same sector
KARO PHARMA AS has a score of 82 for 2025, rank 888 of 38,670 in the sector.
Strongest: Profitability: percentile 95 against peers, operating margin 24.6% against a median of 3.2%. Liquidity: percentile 82 against peers, current ratio 2.39 against a median of 1.38.
No area is clearly below its peers.
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
KARO PHARMA AS had an operating margin of 24.6% and an equity ratio of 60.6% in 2025, and ranks 888 of 38,670 in Handel.
From 2024 to 2025: the equity ratio rose from 40.4% to 60.6% and revenue grew by 11%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 365 MNOK and 1,601 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 1,601 MNOK |
| EV/EBIT | 8.0 | 1,558 MNOK |
| P/B | 1.0 | 365 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- positive
Upper quartile on profitability, solidity and liquidity. What sets this company apart from the rest of the sector?
Based on: Operating margin 24.6% (median 3.2%); Equity ratio 60.6% (median 32.6%); Current ratio 2.39 (median 1.38).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 4.1% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2017, the sector's weakest year, for this company.
The sector's weakest year was 2017, with a median operating margin of −65.6%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 95 | weight 30% |
|---|---|---|
| Solidity | 81 | weight 25% |
| Liquidity | 82 | weight 15% |
| Growth | 62 | weight 15% |
| Consistency | 80 | weight 15% |
Durability: 74 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is KARO PHARMA AS?
The operating margin was 24.6% in 2025, against a median of 3.2% among companies in the Morning class Medium in the same sector. Return on assets was 35.7%.
How solid is KARO PHARMA AS?
The equity ratio was 60.6% in 2025 (median 32.6%). Debt-to-equity was 0.65 (median 2.03).
What is the liquidity of KARO PHARMA AS like?
The current ratio was 2.39 in 2025 (median 1.38).
How does KARO PHARMA AS compare in Handel?
KARO PHARMA AS ranks 888 of 38,670 in Handel for 2025. Among companies in the Morning class Medium it is number 45 of 2,203. Revenue changed by 10.7% from the year before.
From the Central Coordinating Register
- Org. no.
- 917296200
- Legal form
- AS
- Sector
- Handel (46.460)
- Morning company class
- Medium
- Employees
- 23 registered 10 October 2026
- Founded
- 31 January 1940 86 years in operation
- Share capital
- 6.80 MNOK
- Business address
- Østensjøveien 27, 0661 OSLO
- Municipality
- Oslo rank 63–221 of 357 in Norway
- Latest accounts filed
- 2025
- Website
- www.karopharma.com
- LEI
- 5967007LIEEXZXFKRS82 not renewed (lapsed)
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Esad Toric
- Chair of the board
- Christoffer Erik Mathies Lorentzen
- Board member
- Synnøve Elisabeth With Notø
- Board member
- Egil Mølsted Madsen
- Auditor
- KPMG AS
- Accountant
- ECIT NORIAN AS
- Accountant
- VAAK REGNSKAP AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
- Parent company
- No known owner
Source: GLEIF (Global Legal Entity Identifier Foundation), fetched 30 October 2026. The parent is the one the company itself reported to GLEIF.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 26 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 70 | 70 | 82 | |
| Rank | 6,332 | 4,810 | 888 | |
| Operating margin | 23.6% | 25.1% | 24.6% | |
| Return on assets | 39.5% | 38.2% | 35.7% | |
| Equity ratio | 33.6% | 40.4% | 60.6% | |
| Current ratio | 1.38 | 1.55 | 2.39 | |
| Revenue growth | – | 3.2% | 10.7% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 692.1 MNOK | 714.3 MNOK | 790.4 MNOK |
| Operating profit | 163.2 MNOK | 179.5 MNOK | 194.6 MNOK |
| Profit before tax | 161.4 MNOK | 187.5 MNOK | 205.3 MNOK |
| Net profit | 125.9 MNOK | 146.3 MNOK | 160.1 MNOK |
| Financial expenses | 16.2 MNOK | 4.5 MNOK | 9.8 MNOK |
| Total assets | 449.6 MNOK | 502.2 MNOK | 603.2 MNOK |
| Current assets | 410.9 MNOK | 465.6 MNOK | 567.8 MNOK |
| Equity | 151.0 MNOK | 202.8 MNOK | 365.4 MNOK |
| Retained earnings | 142.5 MNOK | 194.3 MNOK | 356.9 MNOK |
| Total liabilities | 298.5 MNOK | 299.4 MNOK | 237.8 MNOK |
| Current liabilities | 298.5 MNOK | 299.4 MNOK | 237.8 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 26 October 2026, accounts id 6766256.
Further
Similar companies
- BJØRKLUND GULLBØRSEN AS index 83, rank 824 · compare
- NORBYGATA ENGROS AS index 82, rank 899 · compare
- VESTEY FOODS NORGE AS index 82, rank 903 · compare
- NORSPRAY AS index 82, rank 913 · compare
- REBIL HOLDING AS index 82, rank 951 · compare